- The European Medicines Agency (EMA) has finalized to update the product information of COVID-19 vaccines developed by Johnson & Johnson (NYSE:JNJ) and AstraZeneca plc (NASDAQ:AZN) to reflect several newly detected side effects.
- The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has finalized the updates to the product information of J&J’s (JNJ) single-dose shot to indicate “swollen lymph nodes, unusual or decreased feeling in the skin, tinnitus, diarrhea, and vomiting,” as potential side effects.
- EMA said that for AstraZeneca’s vaccine, the product information would be updated to reflect Guillain-Barré syndrome (GBS) as a side effect.
- Related Content: European Medicine Agency Lists Guillain-Barré Syndrome As Rare Side Effect For JNJ COVID-19 Vaccine.
- Price Action: JNJ shares are down 0.20% at $172 during the market session on the last check Wednesday.
- Photo by Johaehn from Pixabay
Cisco Says ‘We Have Now Made The Decision To Begin An Orderly Wind-Down Of Our Business In Russia And Belarus’
"We Are Focused On Ensuring Impacted Employees In Russia And Belarus Are Treated With Respect And Have Our Support Through This Transition"
